Full-Time

Director – Strategy & Operations

Supply Chain / CMC

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$200k - $250k/yr

Senior

Palo Alto, CA, USA + 1 more

More locations: San Francisco, CA, USA

Hybrid role requiring in-office collaboration 3x per week in San Francisco, CA & Palo Alto, CA offices.

Category
Supply Chain Management
Operations & Logistics
Required Skills
Financial analysis
Risk Management
Requirements
  • Passion for getting lifesaving medicines into the hands of patients quickly, efficiently, and compliantly
  • Undergraduate or graduate degree focusing on the healthcare business/life sciences industry
  • Experience working on supply chain and CMC projects, including creating and monitoring key performance metrics, with direct biopharma expertise
  • 3-5+ years of experience in life sciences consulting/investment banking preferred
  • Excellent project management skills and ability to handle multiple projects simultaneously
  • Ability to work independently and as part of a team
  • Must be comfortable with ambiguity
  • Proactive problem solver
  • Fast (extremely fast) learner
  • Strong communication skills
  • Strong leadership skills and ability to influence functional stakeholders to set direction, align work efforts, and ensure outstanding execution
  • The ability to travel (up to 20% of the time) is required
Responsibilities
  • Work with the Commercial team to maintain an updated demand forecast, and integrate it into the supply forecast
  • Ensure alignment between the CMC/Supply team and other teams, including FP&A, Accounting, Legal, Business Development, Commercial Operations, the CFO, and the CEO of BridgeBio
  • Identify strategic investments that BridgeBio can make to its CMC processes/supply chain and model the risk-adjusted NPV to determine which should be pursued
  • Contribute to the ongoing development and maintenance of integrated cross-functional plans to enable accurate financial analysis, resource forecasting, and deadline management
  • Define and track key performance metrics for CMC/Supply Chain risk management, ensuring potential issues are identified early and proactively addressed through contingency planning and cross-functional coordination
  • Translate technical CMC/Supply Chain objectives into clear business deliverables/presentations to the Executive Team, functional heads, and other key stakeholders
Desired Qualifications
  • Master’s degree in chemistry/chemical engineering, MBA, or PhD preferred but not required
  • 3-5+ years of experience in life sciences consulting/investment banking preferred

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. The company generates revenue through drug development, licensing agreements, and partnerships, with a diverse pipeline of over 15 drug programs aimed at 20 different genetic diseases. Their culture promotes independent thinking and transparency, facilitating quick, data-driven decisions to accelerate the drug development process.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent approval of acoramidis in Japan boosts BridgeBio's market presence.
  • ATTRibute-CM study shows significant reduction in mortality and hospitalization rates.
  • Growing demand for genetic therapies aligns with BridgeBio's mission and offerings.

What critics are saying

  • Competition from Alnylam's Amvuttra may impact market share for ATTR amyloidosis.
  • Financial risk from $500 million convertible notes if revenue projections fall short.
  • Dependency on PANTHERx Rare for distribution may pose supply chain challenges.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focuses on genetic diseases with well-understood genetic causes for targeted therapies.
  • Leverages genome sequencing and molecular biology for innovative treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

0%

2 year growth

-1%
Stock Titan
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio Pharma (Nasdaq: BBIO) announced its upcoming presentations at the Heart Failure 2025 conference in Belgrade, Serbia from May 17-20, 2025.

TradingView
May 12th, 2025
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC

BridgeBio to present clinical outcomes, Quality of Life measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM study at the Annual Congress of the Heart Failure Association of the ESC.

BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

BioSpace
Mar 25th, 2025
Bridgebio To Present Cardiovascular Outcomes Data In Patients With Variant And Wild-Type Transthyretin Amyloid Cardiomyopathy (Attr-Cm) From The Attribute-Cm Study At The Acc Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.Flatboard Poster Presentations:Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid CardiomyopathyPresenter: Margot Davis, M.D. of Vancouver General Hospital, CADate: Monday, March 31 at 9:00 am CT/10:00 am ETAcoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ETIn Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsPresenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USADate: Monday, March 31 at 9:00 am CT/10:00 am ETRobustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity AnalysesPresenter: Jan Griffin, M.D

Value the Markets
Mar 24th, 2025
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis

Amvuttra will compete with Pfizer's Vyndaqel and BridgeBio's Attruby.